Journal of Clinical Immunology

, Volume 17, Issue 2, pp 160–166 | Cite as

Elevation of Bioactive Transforming Growth Factor-β in Serum from Patients with Chronic Fatigue Syndrome

  • Adrienne L. Bennett
  • Chun C. Chao
  • Shuxian Hu
  • Dedra Buchwald
  • Laura R. Fagioli
  • Peter H. Schur
  • Phillip K. Peterson
  • Anthony L. Komaroff

Abstract

The level of bioactive transforming growth factor-β (TGF-β) was measured in serum from patients with chronic fatigue syndrome (CFS), healthy control subjects, and patients with major depression, systemic lupus erythematosis (SLE), and multiple sclerosis (MS) of both the relapsing/remitting (R/R) and the chronic progressive (CP) types. Patients with CFS had significantly higher levels of bioactive TGF-β levels compared to the healthy control, major depression, SLE, R/R MS, and CP MS groups (P < 0.01). Additionally, no significant differences were found between the healthy control subjects and any of the disease comparison groups. The current finding that TGF-β is significantly elevated among patients with CFS supports the findings of two previous studies examining smaller numbers of CFS patients. In conclusion, TGF-β levels were significantly higher in CFS patients compared to patients with various diseases known to be associated with immunologic abnormalities and/or pathologic fatigue. These findings raise interesting questions about the possible role of TGF-β in the pathogenesis of CFS.

Transforming growth factor-β chronic fatigue syndrome major depression systemic lupus erythematosis multiple sclerosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Holmes GP, Kaplan JE, Gantz NM, Komaroff AL, Schonberger LB, Straus SE, Jones JF, DuBois RE, Cunningham-Rundles C, Pahwa S, Tosato G, Zegans LS, Purtilo DT, Brown N, Schooley RT, Brus I: Chronic fatigue syndrome: A working case definition. Ann Intern Med 108:387–389, 1988Google Scholar
  2. 2.
    Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A: The chronic fatigue syndrome: A comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 121:953–959, 1994Google Scholar
  3. 3.
    Lloyd AR, Wakefield D, Hickie I: Immunity and the pathophysiology of chronic fatigue syndrome. In Chronic Fatigue Syndrome (Ciba Foundation Symposium 173), GR Bock, J Whelan (eds). New York, John Wiley & Sons, 1993, pp 176–192Google Scholar
  4. 4.
    Barker E, Fujimura SF, Fadem MB, Landay AL, Levy JA: Immunologic abnormalities associated with chronic fatigue syndrome. Clin Infect Dis 18 (Suppl 1):S136-S141, 1994Google Scholar
  5. 5.
    McDonald EM, Mann AH, Thomas HC: Interferons as mediators of psychiatric morbidity: An investigation in a trial of recombinant α-interferon in hepatitis-B carriers. Lancet 2:1175–1178, 1987Google Scholar
  6. 6.
    Krueger JM, Majde JA: Sleep as a host defense: Its regulation by microbial products and cytokines. Clin Immunol Immunopathol 57:188–199, 1990Google Scholar
  7. 7.
    Linde A, Andersson B, Svenson SB, Ahrne H, Carlsson M, Forsberg P, Hugo H, Karstorp A, Lenkei R, Lindwall A, Loftenius A, Sall C, Andersson J: Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. J Infect Dis 165:994–1000, 1992Google Scholar
  8. 8.
    Cheney PR, Dorman SE: Interleukin-2 and the chronic fatigue syndrome. Ann Intern Med 110:321, 1989Google Scholar
  9. 9.
    Chao CC, Gallagher M, Phair J, Peterson PK: Serum neopterin and interleukin-6 levels in chronic fatigue syndrome. J Infect Dis 162:1412–1413, 1990Google Scholar
  10. 10.
    Ho-Yen DO, Carrington D, Armstrong AA: Myalgic encephalomyelitis and alpha-interferon. Lancet 1:125, 1988Google Scholar
  11. 11.
    Patarca R, Klimas NG, Lugtendorf S, Antoni M, Fletcher MA: Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: Interrelations with cellular sources and patterns of soluble immune mediator expression. Clin Infect Dis 18 (Suppl 1):S147-S153, 1994Google Scholar
  12. 12.
    Straus SE, Dale JK, Peter JB, Dinarello CA: Circulating lymphokine levels in chronic fatigue syndrome. J Infect Dis 160:1085–1086, 1989Google Scholar
  13. 13.
    Lloyd A, Gandevia S, Brockman A, Hales J, Wakefield D: Cytokine production and fatigue in patients with chronic fatigue syndrome and healthy control subjects in response to exercise. Clin Infect Dis 18 (Suppl 1):S142-S146, 1994Google Scholar
  14. 14.
    Chao CC, Janoff EN, Hu S, Thomas K, Gallagher M, Tsang M, et al.: Altered cytokine release in peripheral blood mononuclear cell cultures from patients with chronic fatigue syndrome. Cytokine 3:292–398, 1991Google Scholar
  15. 15.
    Peterson PK, Sirr SA, Grammith FC, Schenk C, Pheley AM, Hu S, Chao CC: Effects of mild exercise on cytokines and cerebral blood flow in chronic fatigue syndrome patients. Clin Diag Lab Immunol 1:222–226, 1994Google Scholar
  16. 16.
    Sporn MB, Roberts AB, Wakefield LM, Assoian RK: Transforming growth factor-β: Biological function and chemical structure. Science 233:532–534, 1986Google Scholar
  17. 17.
    Sporn MB, Roberts AB: Introduction: What is TGF-β? In Clinical Applications of TGF-β (Ciba Foundation Symposium 157), GR Bock, J Marsh (eds). New York, John Wiley & Sons, 1991, pp 1–5Google Scholar
  18. 18.
    Massague J: The transforming growth factor-β family. Annu Rev Cell Biol 6:597–641, 1990Google Scholar
  19. 19.
    Roberts AB, Sporn MB: The transforming growth factor-βs. In Handbook of Experimental Pharmacology, Peptide Growth Factors and Their Receptors, Vol 95, Part 1, MB Sporn, AB Roberts (eds). Heidelberg, Springer-Verlag, 1990, pp 419–472Google Scholar
  20. 20.
    Miyazono K, Yuki K, Takaku F, Wernstedt C, Kanzaki T, Olofsson A, Hellman U, Heldin CH: Latent forms of TGF-β: Structure and biology. Ann NY Acad Sci 593:51–58, 1990Google Scholar
  21. 21.
    Ruscetti F, Varesio L, Ochoa A, Ortaldo J: Pleiotropic effects of transforming growth factor-β on cells of the immune system. Ann NY Acad Sci 685:488–500, 1993Google Scholar
  22. 22.
    Fontana A, Constam DB, Frei K, Malipiero U, Pfister HW. Modulation of the immune response by transforming growth factor beta. Int Arch Allergy Immunol 99:1–7, 1992Google Scholar
  23. 23.
    Lucas C, Wallick S, Fendly BM, Figarit I, Palladino MA: TGF-β: A possible autocrine immune regulator. In Clinical Applications of TGF-β (Ciba Foundation Symposium 157), GR Bock, J Marsh (eds). New York, John Wiley & Sons, 1991, pp 98–114Google Scholar
  24. 24.
    Wahl SM, Costa GL, Mizel DE, Allen JB, Skaleric U, Mangan DF: Role of transforming growth factor beta in the pathophysiology of chronic inflammation. J Periodontol 64:450–455, 1993Google Scholar
  25. 25.
    Smith EA, LeRoy EC: A possible role for transforming growth factor-β in systemic sclerosis. J Invest Dermatol 95:125S-127S, 1990Google Scholar
  26. 26.
    Kulozik M, Hogg A, Lankat-Buttgereit B, Krieg T: Co-localization of transforming growth factor β2 with α1(1) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 86:917–922, 1990Google Scholar
  27. 27.
    Kanai H, Mitsuhashi H, Ono K, Yano S, Naruse T: Increased excretion of urinary transforming growth factor beta in patients with focal glomerular sclerosis. Nephron 66:391–395, 1994Google Scholar
  28. 28.
    Deguchi Y, Kishimoto S: Spontaneous activation of Transforming growth factor-β gene transcription in broncho-alveolar mononuclear cells of individuals with systemic autoimmune diseases with lung involvement. Lupus 1:27–30, 1991Google Scholar
  29. 29.
    Dang H, Geiser AG, Letterio JJ, Nakabayashi T, Kong L, Fernandes G, Talal N: SLE-like autoantibodies and sjogren's syndrome-like lymphoproliferation in TGF-β knockout mice. J Immunol 155:3205–3212, 1995Google Scholar
  30. 30.
    Horwitz DA, Wang H, Gray JD: Cytokine gene profile in circulating blood mononuclear cells from patients with systemic lupus erythematosis: Increased interleukin-2 but not interleukin-4 mRNA. Lupus 3:423–428, 1994Google Scholar
  31. 31.
    Rieckmann P, Albrecht BA, Kitze B, Weber T, Tumani H, Broocks A, Luer W, Helwig A, Poser S: Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 37:82–88, 1995Google Scholar
  32. 32.
    Link J, Soderstrom M, Olsson T, Hojeberg B, Ljungdahl A, Link H: Increased transforming growth factor-β, interleukin-4, and interferon-γ in multiple sclerosis. Ann Neurol 36:379–386, 1994Google Scholar
  33. 33.
    Link J, He B, Navikas V, Palasik W, Fredrikson S, Soderstrom M, Link H: Transforming growth factor-β1 suppresses autoantigen-induced expression of proinflammatory cytokines but not of interleukin-10 in multiple sclerosis and myasthenia gravis. J Neuroimmunol 58:21–35, 1995Google Scholar
  34. 34.
    Beck J, Rondot P, Jullien P, Wietzerbin J, Lawrence DA: TGF-β-like activity produced during regression of exacerbations in multiple sclerosis. Acta Neurol Scand 84:452–455, 1991Google Scholar
  35. 35.
    Hafler DA, Chofflon M, Kurt-Jones E, Weiner HL: Interleukin-1 corrects the defective autologous mixed lymphocyte response in multiple sclerosis. Clin Immunol Immunopathol 58:115–125, 1991Google Scholar
  36. 36.
    Kekow J, Wachsman W, McCutchan JA, Cronin M, Carson DA, Lotz M: Transforming growth factor β and noncytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection. Proc Natl Acad Sci USA 87:8321–8325, 1990Google Scholar
  37. 37.
    Landay AL, Jessop C, Lennette ET, Levy JA: Chronic fatigue syndrome: Clinical condition associated with immune activation. Lancet 338:707–712, 1991Google Scholar
  38. 38.
    Straus SE, Fritz S, Dale JK, Gould B, Strober W: Lymphocyte phenotype and function in the chronic fatigue syndrome. J Clin Immunol 13:30–40, 1993Google Scholar
  39. 39.
    Constam DB, Phillip J, Malipiero UV, ten Dijke P, Schachner M, Fontana A: Differential expression of transforming growth factor-β1, β2, and β3 by glioblastoma cells, astrocytes, and microglia. J Immunol 148:1404–1410, 1992Google Scholar
  40. 40.
    da Cunha A, Jefferson JA, Jackson RW, Vitkovic L: Glial cell-specific mechanisms of TGF-β1 induction by IL-1 in cerebral cortex. J Neuroimmunol 42:71–86, 1993Google Scholar
  41. 41.
    Wahl SM, Allen JB, McCartney-Francis N, Morganti-Kossmann MC, Kossmann T, Ellingsworth L, Mai UEH, Mergenhagen SE, Orenstein JM: Macrophage-and astrocyte-derived transforming growth factor β as a mediator of central nervous system dysfunction in acquired immune deficiency syndrome. J Exp Med 173: 981–991, 1991Google Scholar
  42. 42.
    Chao CC, Hu S, Frey WH, II, Ala T, Tourtellotte WW, Peterson PK: Transforming growth factor-β in Alzheimer's disease. Clin Diagn Lab Immunol 1:109–110, 1994Google Scholar
  43. 43.
    Chao CC, Hu S, Kravitz FH, Anderson WR, Tsang M, Peterson PK: Transforming growth factor-β protects human neurons against β-amyloid-induced injury. Mol Chem Neuropathol 23:159–178, 1994Google Scholar

Copyright information

© Plenum Publishing Corporation 1997

Authors and Affiliations

  • Adrienne L. Bennett
    • 1
  • Chun C. Chao
    • 2
  • Shuxian Hu
    • 2
  • Dedra Buchwald
    • 3
  • Laura R. Fagioli
    • 1
  • Peter H. Schur
    • 4
  • Phillip K. Peterson
    • 2
  • Anthony L. Komaroff
    • 1
  1. 1.Chronic Fatigue Syndrome Cooperative Research Center and Division of General Medicine and Primary CareBrigham and Women's Hospital, and Harvard Medical SchoolBoston
  2. 2.Department of MedicineHennepin County Medical Center, Neuroimmunobiology and Host Defense Laboratory, Minneapolis Medical Research Center, and University of Minnesota Medical SchoolMinneapolis
  3. 3.Department of MedicineUniversity of WashingtonSeattle
  4. 4.Lupus Center, Division of Rheumatology and ImmunologyBrigham and Women's Hospital, and Harvard Medical SchoolBoston

Personalised recommendations